Page last updated: 2024-08-25

bendamustine hydrochloride and Minimal Disease, Residual

bendamustine hydrochloride has been researched along with Minimal Disease, Residual in 18 studies

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (16.67)	29.6817
2010's	10 (55.56)	24.3611
2020's	5 (27.78)	2.80

Authors

Authors	Studies
Assouline, S; Boyer, M; Cartron, G; Chyla, B; D'Rozario, J; de la Serna, J; Eichhorst, BF; Jaeger, U; Jiang, Y; Kater, AP; Kipps, TJ; Lamanna, N; Lefebure, M; Lu, T; Mellink, C; Montillo, M; Owen, CJ; Panchal, A; Robak, T; Seymour, JF; Wu, JQ	1
Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C	1
Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C	1
Belada, D; Cheson, BD; Fingerle-Rowson, G; Gribben, J; Harbron, C; Hoster, E; Kahl, B; Kehden, B; Mundt, K; Nicolas-Virelizier, E; Pott, C; Sehn, LH; Spielewoy, N; Wassner-Fritsch, E	1
Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M	1
Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kreuzer, KA; Langerbeins, P; Stilgenbauer, S; von Tresckow, J; Wendtner, CM	1
Assouline, S; Boyer, M; Cartron, G; D'Rozario, J; De la Serna, J; Eichhorst, B; Gerecitano, J; Hillmen, P; Humerickhouse, R; Humphrey, K; Jaeger, U; Kater, AP; Kipps, TJ; Li, Y; Mobasher, M; Montillo, M; Owen, C; Punnoose, EA; Robak, T; Seymour, JF	1
Bosch, F; Böttcher, S; Foà, R; Gresko, E; Ilhan, O; Knauf, W; Leblond, V; Lundberg, L; Mikuskova, E; Moore, T; Morris, T; Renner, C; Robson, S; Stilgenbauer, S; Tausch, E; Woszczyk, D	1
Edwin, NC; Kahl, B	1
Boyer, M; Eichhorst, B; Hillmen, P; Humphrey, K; Jiang, Y; Kater, AP; Kipps, TJ; Langerak, AW; Mobasher, M; Owen, C; Punnoose, EA; Seymour, JF; Verdugo, M; Wang, J; Wu, J	1
Nakaseko, C	1
Burger, JA; Estrov, Z; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Thompson, PA; Wang, X; Wierda, WG; Xiao, L	1
Allsup, D; Bloor, A; Collett, L; Hillmen, P; Hockaday, A; Howard, DR; Munir, T; Oughton, JB; Phillips, D; Rawstron, AC	1
Barr, PM; Bernstein, SH; Blum, KA; Cashen, AF; Chen, RW; Cheson, BD; Constine, L; Faham, M; Fenske, TS; Fisher, RI; Forman, SJ; Friedberg, JW; Kahl, BS; Kahwash, S; Leblanc, M; Leonard, JP; Li, H; Phillips, T; Rimsza, LM; Shea, TC; Smith, SM; Wilkins, J	1
Carter, NJ; Plosker, GL	1
Ahmadi, T; Maniar, T; Schuster, S; Stadtmauer, E	1
Hallek, M	1
Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D	1

Reviews

5 review(s) available for bendamustine hydrochloride and Minimal Disease, Residual

Article	Year
Evolving treatment strategies in mantle cell lymphoma. Best practice & research. Clinical haematology, 2018, Volume: 31, Issue:3 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Cytarabine; Humans; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Neoplasm, Residual; Rituximab; Stem Cell Transplantation	2018
[Treatment of transplant-eligible symptomatic multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning	2014
Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma. Drugs, 2008, Volume: 68, Issue:18 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials as Topic; Drug Resistance, Neoplasm; Half-Life; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Neoplasm, Residual; Nitrogen Mustard Compounds; Rituximab	2008
Chronic lymphocytic leukemia: new concepts and emerging therapies. Current treatment options in oncology, 2009, Volume: 10, Issue:1-2 Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; Bendamustine Hydrochloride; CD5 Antigens; Disease Progression; Drugs, Investigational; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Neoplasm, Residual; Nitrogen Mustard Compounds; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy	2009
State-of-the-art treatment of chronic lymphocytic leukemia. Hematology. American Society of Hematology. Education Program, 2009 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Combined Modality Therapy; Cytostatic Agents; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Salvage Therapy; Thionucleotides; Transplantation, Homologous; Vidarabine	2009

Trials

11 trial(s) available for bendamustine hydrochloride and Minimal Disease, Residual

Article	Year
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 2022, 08-25, Volume: 140, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Rituximab; Sulfonamides	2022
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. The Lancet. Haematology, 2022, Volume: 9, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides	2022
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. The New England journal of medicine, 2023, May-11, Volume: 388, Issue:19 Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab	2023
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British journal of haematology, 2021, Volume: 193, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine	2021
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future oncology (London, England), 2018, Volume: 14, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Bridged Bicyclo Compounds, Heterocyclic; Humans; Induction Chemotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm, Residual; Purines; Quinazolinones; Sulfonamides; Treatment Outcome	2018
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England journal of medicine, 2018, Mar-22, Volume: 378, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Recurrence; Rituximab; Sulfonamides; Tumor Lysis Syndrome; Young Adult	2018
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. Leukemia, 2018, Volume: 32, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Remission Induction; Rituximab; Salvage Therapy; Survival Rate	2018
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 02-01, Volume: 37, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Recurrence; Rituximab; Sulfonamides; Time Factors	2019
Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial. Trials, 2016, 09-20, Volume: 17, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Protocols; Cyclophosphamide; Drug Dosage Calculations; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Research Design; Time Factors; Treatment Outcome; United Kingdom; Vidarabine	2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. British journal of haematology, 2017, Volume: 176, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Transplantation, Autologous; Treatment Outcome; Vincristine; Young Adult	2017
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Sep-10, Volume: 29, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine	2011

Other Studies

2 other study(ies) available for bendamustine hydrochloride and Minimal Disease, Residual

Article	Year
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia, 2020, Volume: 34, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Rituximab	2020
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer, 2016, Feb-15, Volume: 122, Issue:4 Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase	2016

Article

Year

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

Leukemia, 2020, Volume: 34, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Rituximab

2020

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.

Cancer, 2016, Feb-15, Volume: 122, Issue:4

Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; beta 2-Microglobulin; Bone Marrow; Case-Control Studies; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Piperidines; Prognosis; Proportional Hazards Models; Pyrazoles; Pyrimidines; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2016